Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: From man to mouse and back

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2423-2425

  Devuyst, Olivier ^a,b   Wang, Xueqi ^a,c   Serra, Andreas ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

ADPKD; PKD1; renal cysts; Tolvaptan

Indexed keywords

ADENYLATE CYCLASE; AQUAPORIN 2; CALCIUM ION; CHLORIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MOZAVAPTAN; POLYCYSTIN 1; POLYCYSTIN 2; TOLVAPTAN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

CALCIUM CELL LEVEL; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESEARCH; ENZYME ACTIVITY; FLUID INTAKE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; KIDNEY COLLECTING TUBULE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EXCRETION; LOW DRUG DOSE; NONHUMAN; NOTE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PKD1 GENE; PKD2 GENE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SPECIES DIFFERENCE; TREATMENT OUTCOME; URINE OSMOLALITY; URINE VOLUME;

ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; FEMALE; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECEPTORS, VASOPRESSIN;

EID: 79961037709     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr380     Document Type: Note

References (25)

1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009;76:149-168
2. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-157
3. Terryn S, Ho A, Beauwens R et al. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2011 PMID: 21255645
4. Torres VE. Role of vasopressin antagonists. Clin J Am Soc Nephrol 2008;3:1212-1218
5. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17:2220-2227 (Pubitemid 44141912)
6. Wang X, Wu Y, Ward CJ et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-108
7. Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study. Am J Kidney Dis 2011 May; 57(5):692-9
8. Meijer E, Gansevoort RT, de Jong PE et al. Therapeutic potential of a vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 2011
9. Serra A, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:820-829
10. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:830-840
11. Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010;363:879-881
12. Piontek K, Menezes LF, Garcia-Gonzalez MA et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 2007;13:1490-1495 (Pubitemid 350224245)
13. Belge H, Gailly P, Schwaller B et al. Renal expression of parvalbumin is critical for NaCl handling and response to diuretics. Proc Natl Acad Sci U S A 2007;104:14849-14854 (Pubitemid 350003231)
14. Ahrabi AK, Jouret F, Marbaix E et al. Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion. Nephrol Dial Transplant 2010;25:1067-1078
15. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10:363-364 (Pubitemid 38508512)
16. Bachinsky DR, Sabolic I, Emmanouel DS et al. Water channel expression in human ADPKD kidneys. Am J Physiol 1995;268:F398-F403
17. Devuyst O, Burrow CR, Smith BL et al. Expression of aquaporins-1 and-2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol 1996;271:F169-F183
18. Ahrabi AK, Terryn S, Valenti G et al. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 2007;18:1740-1753 (Pubitemid 46870311)
19. Perucca J, Bichet DG, Bardoux P et al. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008;19:1721-1731
20. Parreira KS, Debaix H, Cnops Y et al. Expression patterns of the aquaporin gene family during renal development: influence of genetic variability. Pflügers Arch 2009;458:745-759
21. Wagner CA, Devuyst O, Belge H et al. The rhesus protein RhCG: a new perspective in ammonium transport and distal urinary acidification. Kidney Int 2011;79:154-161
22. Kalenga K, Persu A, Goffin E et al. Intrafamilial phenotype variability in nephrogenic diabetes insipidus. Am J Kidney Dis 2002;39:737-743 (Pubitemid 34263347)
23. Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol 2005;288:F881-F896 (Pubitemid 40569752)
24. Carmosino M, Brooks HL, Cai Q et al. Axial heterogeneity of vasopressin receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol 2007;292:F351-F360 (Pubitemid 46115930)
25. Mutig K, Paliege A, Kahl T et al. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol 2007;293:F1166-F1177 (Pubitemid 47583950)